Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

134A randomised prospective trial of tacrolimus-based steroid avoidance in renal transplantation with either alemtuzumab induction or, basiliximab induction and mycophenolate mofetil maintenance therapy.

Trial Profile

134A randomised prospective trial of tacrolimus-based steroid avoidance in renal transplantation with either alemtuzumab induction or, basiliximab induction and mycophenolate mofetil maintenance therapy.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Tacrolimus (Primary) ; Basiliximab; Methylprednisolone; Mycophenolate mofetil
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SALAMI
  • Most Recent Events

    • 19 Sep 2013 Results published in Transplantation.
    • 22 May 2013 Results at 3 years presented at the American Transplant Congress - 13th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
    • 04 May 2011 Results presented at the American Transplant Congress -- 11th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top